

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 2, 2023

---

**ARCUTIS BIOTHERAPEUTICS, INC.**  
(Exact name of registrant as specified in its charter)

---

Delaware  
(State or other jurisdiction  
of incorporation)

001-39186  
(Commission  
File Number)

81-2974255  
(IRS Employer  
Identification Number)

3027 Townsgate Road, Suite300  
Westlake Village, CA 91361  
(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (805) 418-5006

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.0001 per share	ARQT	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.07 Submission of Matters to a Vote of Security Holders**

On May 31, 2023, Arcutis Biotherapeutics, Inc., (the "Company") held its 2023 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on three proposals, each of which is described in more detail in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 18, 2023. Only stockholders of record as of the close of business on April 3, 2023, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, 61,360,936 shares of the Company's common stock were outstanding, and entitled to vote at the Annual Meeting. The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows:

Proposal 1. The election of three Class II directors to hold office until the 2026 annual meeting of stockholders or until their respective successor is elected:

<b>Nominee</b>	<b>Votes for</b>	<b>Votes withheld</b>	<b>Broker Non-Votes</b>
Patrick J. Heron	44,208,982	6,933,977	3,771,693
Neha Krishnamohan	50,425,906	717,053	3,771,693
Todd Franklin Watanabe	45,416,267	5,726,692	3,771,693

Proposal 2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023:

<b>Votes for</b>	<b>Votes against</b>	<b>Abstentions</b>	<b>Broker Non-Votes</b>
54,541,027	358,765	14,860	—

Proposal 3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers:

<b>Votes for</b>	<b>Votes against</b>	<b>Abstentions</b>	<b>Broker Non-Votes</b>
43,770,313	7,343,874	28,772	3,771,693

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

June 2, 2023

**ARCUTIS BIOTHERAPEUTICS, INC.**

By: /s/ Scott L. Burrows

Scott L. Burrows

*Chief Financial Officer*

*(Principal Financial and Accounting Officer)*